Phase II clinical trial of N-(4-hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia

Clinical Cancer Research

Volumn 8, Issue 9, 2002, Pages 2835-2842

  Singletary, S Eva ^a   Atkinson, Edward N ^a   Hoque, Ashraful ^a   Sneige, Nour ^a   Sahin, Ayse A ^a   Fritsche Jr , Herbert A ^a   Lotan, Reuben ^a   Lu, Tao ^a   Hittelman, Walter N ^a   Bevers, Therese B ^a   Stelling, Carol B ^a   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FENRETINIDE; KI 67 ANTIGEN; PLACEBO; PROTEIN; PROTEIN P53; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER SURGERY; CARCINOMA IN SITU; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DNA CONTENT; DRUG EFFICACY; DRUG RESPONSE; EARLY CANCER; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HUMAN TISSUE; LABELING INDEX; MAJOR CLINICAL STUDY; NAUSEA; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; SAMPLE SIZE; TUMOR BIOPSY; VERTIGO;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DNA, NEOPLASM; FEMALE; FENRETINIDE; HUMANS; KI-67 ANTIGEN; MASTECTOMY; MIDDLE AGED; NEOPLASM PROTEINS; PREMEDICATION; PRODRUGS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, RETINOIC ACID; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036718566     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: Long-term follow-up and causes of death
2. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
3. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
4. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat
5. Distribution of fenretinide in the mammary gland of breast cancer patients
6. 4-Hydroxyphenylretinamide is a highly selective activator of retinoid receptors
7. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
8. Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation
9. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats
10. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen
11. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl)retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer
12. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer
13. Development of breast cancer chemopreventive drugs
14. Biological activity of all-trans-retinoic acid with and without tamoxifen and α-interferon 2a in breast cancer patients
15. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: Toxicity, pharmacokinetic, and biomarker evaluations
16. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
17. Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells
18. Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells
19. Effect of N-(4-hydroxyphenyl)retinamide on murine mammary tumor cells in cultures
20. Overexpression of HER2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer
21. NEU-protein overexpression in breast cancer - Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
22. Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells
23. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy
24. Differential expression of nuclear retinoid receptors in normal and malignant prostates
25. Novel translational model for breast cancer chemoprevention study: Accrual to a presurgical intervention with tamoxifen and 4-HPR
26. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients
27. N-(4-hydroxyphenyl)retinamide (4-HPR) lowers plasma retinol levels in rats
28. Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations
29. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study
30. Prediction of clinical outcome from primary tamoxifen by expression of biological markers in breast cancer patients
31. A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labeling index in women with primary breast cancer
32. Growth inhibition by retinol of a human breast carcinoma cell line in vitro and in athymic mice
33. Effect of retinoids on xenotransplanted human mammary carcinoma cells in athymic mice
34. Regulation of the human retinoic acid receptor α gene in the estrogen receptor negative human breast carcinoma cell lines SKBR-3 and MDA-MB-435
35. Retinoic acid nuclear receptor α (RAR α) plays a major role in retinoid-mediated inhibition of growth in human breast carcinoma cells
36. Combined effect of tamoxifen or interferon-beta and 4-hydroxyphenylretinamide on the growth of breast cancer cell lines
37. Comparison of I-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines
38. Effects of tamoxifen on telomerase activity in breast carcinoma cell lines
39. Editorial: Accrual to clinical trials
40. Models for early chemoprevention trials in breast cancer
41. Faslodex (ICI 182,780), a novel estrogen receptor downregulator-future possibilities in breast cancer
42. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: A double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients
43. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer
44. Phase I biomarker and toxicity evaluation of LY353381 (a 3rd generation selective estrogen receptor modulator, SERM) in breast cancer
45. Recruitment for complementary/alternative medicine trials: Who participates after breast cancer
46. Reducing patient eligibility criteria in cancer clinical trials
47. A study in contrasts: Eligibility criteria in a twenty-year sample of NSABP and POG clinical trials